Seattle-based biotech company AGC Biologics announced that it will be adding a new preclinical and commercial manufacturing facility to its Yokohama Technical Center in Japan.
The facility will serve as the company’s second manufacturing site in the country as part of an agreement between AGC and Japan’s government to expand the Yokohama Technical Center and add 400 employees.
The $350.5 million building, which is expected to begin operations by 2026, will be mammal-based and produce mammal cell cultures. The facility’s funding comes from Japan’s government, via its Ministry of Economy, Trade and Industry (METI) in an effort to bolster the country’s vaccine production.